You are on page 1of 3

Measurement of OxPL-apoB levels

OxPL-apoB levels were measured in a chemiluminescent immunoassay
using the murine monoclonal antibody E06 that recognizes the
phosphocholine (PC) group on oxidized but not on native phospholipids (Taleb
et al (1) and references therein). E06 similarly recognizes the PC covalently
bound to BSA, as in PC-BSA. A 1:50 dilution of plasma in 1% BSA in TBS was
added to microtiter wells coated with the apoB-100 specific monoclonal
antibody MB47, which binds a saturating amount of apoB-100 to each well,
and biotinylated E06 was then used to determine the content of OxPL-apoB.
These values are reported as nanomolar (nM) PC-OxPL using a standard
curve of nM phosphocholine (PC) equivalents, as recently described (2).
Because each well contains equal numbers of apoB-100 particles, the OxPLapoB value reflects the absolute content of OxPL per a constant amount of
captured apoB lipoprotein. It thus represents an OxPL-apoB value that is
independent of plasma levels of apoB-100 or of LDL cholesterol. Furthermore,
the assay detects only the subset of OxPL detected by antibody E06 and not
all species of OxPL.
The OxPL-apoB assay has historically taken 3
modifications/optimizations to allow easier translation to the bedside. The
assay was set up a priori to quantitate the amount of OxPL bound to apoBcontaining lipoproteins captured on microtiter well plates (3). It was thus
called OxPL/apoB (E06) and initially represented a true ratio by performing 2
measurements- the OxPL measure in one set of plates and the apoB
captured on the plate in a second set of plates (we emphasize that the
denominator is not the plasma level of apoB but reflects how much apoB is
captured on the plates). The ratio of OxPL/apoB was then determined and is
a unitless measure. In this first version of the assay, an anti-apoB antibody
(MB47) that recognizes all apoB-containing lipoproteins was used to capture
a saturating amount of apoB from a 1:50 dilution of plasma sample. The
amount of apoB captured on the plate was then quantitated with a second
anti-apoB antibody and the results expressed in relative light units (RLUs).
This measure represented the denominator of the OxPL-apoB ratio. In
parallel, a second set of plates was coated with MB47 and then the OxPL
content on apoB measured with monoclonal antibody E06 and results
expressed as RLUs. E06 binds to the phosphocholine (PC) headgroup of
oxidized but not normal phospholipids. The ratio OxPL/apoB was then
determined. This assay was designed purposefully this way to make it
independent of plasma apoB and LDL-C levels. With this methodology, all
wells capture the same amount of apoB at plasma apoB levels of 10-20
mg/dl. Virtually all patients have a higher concentration of apoB than 10-20
mg/dl, therefore, all plates would be expected to be equally saturated with
apoB.
A second version of this assay was created in 2006 to reduce the time
and expense of running both assays to determine OxPL/apoB ratio (4). We
determined in larger datasets that assays measuring microtiter well content
of apoB were not needed, and started to report the OxPL/apoB assay as

2.61:2169-79. Lee JH et al. this variable was expressed as OxPL/apoB. Bertoia ML. Biomarkers Med 2011. which represent a variety of species as initially defined by Friedman et al (5) as measured by antibody E06. Oxidation-specific biomarkers and risk of peripheral artery disease. A third version was developed in 2012 (2). This measure reflects the absolute content of OxPL and is not a ratio.78) (4) and pilot-tests showed that OxPL-apoB levels are stable over 24 hours on ice (intraclass correlation coefficient 0.e. Within-person 5-year reproducibility of frozen samples has been shown to be high (r=0. Witztum JL. 4. Kiechl S. J Am Coll Cardiol 2006. Tsimikas S. and not all OxPL.96)(2) as well as frozen samples stored under long term conditions (4. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. using the RLUs from PCBSA standards. Taleb A. The nomenclature is now changed to OxPLapoB to minimize confusion that this measure represents a ratio of OxPL divided by plasma levels of apoB. Because each mole of OxPL contains one mole of PC. Bergmark C. The subset of OxPL recognized by E06. not determining the apoB content of plates. we now convert the RLUs to nanomoles of PC-OxPL and report this as nanoMolar (nM) units PC-OxPL. . E06 recognizes the PC present on BSA similar to the PC in OxPL. we showed that the correlation between OxPL/apoB ratio and OxPL-apoB RLUs was >0. References 1. Willeit J et al. Thus. which is the current version in the TNT paper. we can convert the RLUs of the E06/MB47 measures to OxPL equivalents.41:36070. The rationale for this is that after showing all plates were equally saturated with apoB. we deleted this step in future studies. Tsimikas S. reflecting the fact that this measure quantitates the number of OxPL moles per unit mass of apolipoprotein B-100 present on microtiter well plates (and not the level in the circulation).6-9). we further generated a standard curve by plating phosphocholine-modified bovine serum albumin (PC-BSA) with known amounts of PC as the standard and determining E06 immunoreactivity in RLUs (2). Oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) containing lipoproteins: A biomarker predicting cardiovascular disease and cardiovascular events. Pai JK. i. J Am Coll Cardiol 2003. J Am Coll Cardiol 2013.47:2219-28. 3.5:673-694. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study.995 with similar results on prospective CVD outcomes.OxPL/apoB (E06/MB47) in RLUs. Beyer RW et al. Therefore. In prior studies (1. Tsimikas S. but we never claimed otherwise and stated plainly in the methods that these OxPL.10-12).

6. Arterioscler Thromb Vasc Biol 2007. Orsoni A. Kiechl S. Arai K. Oxidation-specific biomarkers. 12. Vissers MN.60:2218-29. Rodenburg J. 11. Oxidation-specific biomarkers. Willeit J. J Am Coll Cardiol 2014.27:1788-95. Tsimikas S. Oxidized phospholipids. prospective 15-year cardiovascular and stroke outcomes. Leibundgut G. J Lipid Res 2012.5. and risk of fatal and nonfatal coronary events. Mallat Z et al. lipoprotein-associated phospholipase A2 activity. Mallat Z. and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Willeit P. 10. and net reclassification of cardiovascular events.47:1803-10. 8. J Am Coll Cardiol 2012.56:946-55. Arai K. Wiegman A et al.277:7010-20. lipoprotein(a). Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. . Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.59:1426-1437. Willeit J et al.63:1724-1734. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). Berger PB et al. affect fibrinolysis. Tsimikas S. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. Oxidized phospholipids are present on plasminogen.53:1670-8. J Biol Chem 2002. Tsimikas S. and increase following acute myocardial infarction. Friedman P. Steinberg D. Orsoni A et al. lipoprotein(a). Mayr M et al. Dennis EA. J Am Coll Cardiol 2006. Talmud PJ et al. Horkko S. J Am Coll Cardiol 2010. Importance of Schiff base formation and aldol condensation. Duff GW. 9. J Am Coll Cardiol 2012. Witztum JL. 7.